Focus on 2001's Biotech Megadeals
Executive Summary2001 was a banner year for biotech alliances, both in number and dollar volume. IN VIVO charts the biggest of the big: the top five alliances by total deal value.
You may also be interested in...
ICER president Steve Pearson is ‘cautiously optimistic’ that net pricing for acute migraine treatments will align with benefits once discounts are factored in.
Crude heparin supplier Yibin Lihao headlines list of facilities in 12 countries added to the US FDA’s drug GMP import alert.
Tschudin talked to Scrip about taking over as Novartis Pharmaceuticals president, why inclisiran is different from marketed PCSK9 inhibitors and prioritizing investment behind multiple new launches.